Literature DB >> 11545422

Melanoma-associated retinopathy: does autoimmunity prolong survival?

C Chan1, J O'Day.   

Abstract

PURPOSE: To discuss the autoimmune basis of melanoma-associated retinopathy (MAR) and its implications for management and prognosis.
METHODS: An unusual history of a woman with melanoma-associated retinopathy is presented in detail. A review of published reports and a summary of 19 reported cases of MAR provide a basis for discussion.
RESULTS: This case report and other published reports highlight a number of points regarding MAR including the male predominance, prolonged survival in several patients and lack of response to immunosuppression.
CONCLUSIONS: Melanoma-associated retinopathy may prolong the survival of patients with metastatic melanoma through the autoimmune response. Therefore, treatment of visual symptoms with immunosuppression needs to be considered carefully.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11545422     DOI: 10.1046/j.1442-9071.2001.00425.x

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  10 in total

1.  Bilateral diffuse uveal melanocytic proliferation: a management dilemma.

Authors:  Salah Alrashidi; Ayman A Aziz; Hatem Krema
Journal:  BMJ Case Rep       Date:  2014-05-22

2.  Outcomes Associated With Sustained-Release Intraocular Fluocinolone Implants in a Case of Melanoma-Associated Retinopathy Treated Without Systemic Immunosuppression.

Authors:  Eleni Karatsai; Anthony G Robson; Simon R J Taylor
Journal:  JAMA Ophthalmol       Date:  2019-05-01       Impact factor: 7.389

3.  Delayed presentation of melanoma-associated retinopathy and subsequent resolution with cytoreduction surgery.

Authors:  Richard E Stead; Maryke A Fox; Emily Staples; Chea S Lim
Journal:  Doc Ophthalmol       Date:  2013-06-22       Impact factor: 2.379

4.  Bilateral diffuse uveal melanocytic proliferation associated with endometrial carcinoma - multimodal imaging analysis.

Authors:  Zhi-Peng Cai; Hong Zhang; Jin-Jing Zhang; Chuan-Hong Jie; Fang-Tian Dong
Journal:  Int J Ophthalmol       Date:  2022-07-18       Impact factor: 1.645

5.  Cancer-associated retinopathy (CAR) with electronegative ERG: a case report.

Authors:  Griet Goetgebuer; Anna-Maria Kestelyn-Stevens; Jean-Jacques De Laey; Philippe Kestelyn; Bart P Leroy
Journal:  Doc Ophthalmol       Date:  2007-08-25       Impact factor: 2.379

Review 6.  Autoimmune retinopathy: a review and summary.

Authors:  John R Heckenlively; Henry A Ferreyra
Journal:  Semin Immunopathol       Date:  2008-04-12       Impact factor: 9.623

7.  A genetic inference on cancer immune responsiveness.

Authors:  Ena Wang; Lorenzo Uccellini; Francesco M Marincola
Journal:  Oncoimmunology       Date:  2012-07-01       Impact factor: 8.110

8.  TRPM1 Autoantibodies in Melanoma Patients Without Self-Reported Visual Symptoms.

Authors:  Robert M Duvoisin; Gaoying Ren; Tammie L Haley; Matthew H Taylor; Catherine W Morgans
Journal:  Invest Ophthalmol Vis Sci       Date:  2019-05-01       Impact factor: 4.799

9.  IRF5 gene polymorphisms in melanoma.

Authors:  Lorenzo Uccellini; Valeria De Giorgi; Yingdong Zhao; Barbara Tumaini; Narnygerel Erdenebileg; Mark E Dudley; Sara Tomei; Davide Bedognetti; Maria Libera Ascierto; Qiuzhen Liu; Richard Simon; Leah Kottyan; Kenneth M Kaufman; John B Harley; Ena Wang; Steven A Rosenberg; Francesco M Marincola
Journal:  J Transl Med       Date:  2012-08-21       Impact factor: 5.531

10.  T Helper 1 Cellular Immunity Toward Recoverin Is Enhanced in Patients With Active Autoimmune Retinopathy.

Authors:  Steven K Lundy; Enayat Nikoopour; Athanasios J Karoukis; Ray Ohara; Mohammad I Othman; Rebecca Tagett; K Thiran Jayasundera; John R Heckenlively
Journal:  Front Med (Lausanne)       Date:  2018-09-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.